Ocular Hypertension - Pipeline Review, H2 2013

Date: September 20, 2013
Pages: 112
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: OEDACF7AD97EN
Leaflet:

Download PDF Leaflet

Ocular Hypertension - Pipeline Review, H2 2013
Ocular Hypertension - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Ocular Hypertension - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Ocular Hypertension, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ocular Hypertension. Ocular Hypertension - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • A snapshot of the global therapeutic scenario for Ocular Hypertension.
  • A review of the Ocular Hypertension products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Ocular Hypertension pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.
Reasons to buy
  • Identify and understand important and diverse types of therapeutics under development for Ocular Hypertension.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Ocular Hypertension pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Ocular Hypertension Overview
Therapeutics Development
An Overview of Pipeline Products for Ocular Hypertension
Ocular Hypertension Therapeutics under Development by Companies
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Ocular Hypertension Therapeutics - Products under Development by Companies
Companies Involved in Ocular Hypertension Therapeutics Development
Alcon, Inc.
F. Hoffmann-La Roche Ltd.
Bausch & Lomb Incorporated
Allergan, Inc.
QLT Inc.
Santen Pharmaceutical Co., Ltd.
Sylentis
Novagali Pharma SA
Kowa Company, Ltd.
Ono Pharmaceutical Co., Ltd.
Pfizer Inc.
Sun Pharmaceutical Industries Limited
Can-Fite BioPharma Ltd.
Lexicon Pharmaceuticals, Inc.
Cancer Research Technology Limited
LABORATOIRES THEA
Asahi Kasei Pharma
Inotek Pharmaceuticals Corporation
Aerie Pharmaceuticals, Inc.
Icon Bioscience, Inc.
Ocular Hypertension - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
tafluprost - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tafluprost - Drug Profile
Product Description
Mechanism of Action
R&D Progress
latanoprostene bunod - Drug Profile
Product Description
Mechanism of Action
R&D Progress
latanoprostene bunod - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CF-101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
trabodenoson - Drug Profile
Product Description
Mechanism of Action
R&D Progress
K-115 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
latanoprost - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AR-12286 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SYL-040012 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RO-5093151 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
T-2345 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
latanoprost - Drug Profile
Product Description
Mechanism of Action
R&D Progress
aganepag isopropyl - Drug Profile
Product Description
Mechanism of Action
R&D Progress
simenepag isopropyl - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AL-54478 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
brimonidine tartrate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
(tafluprost + timolol maleate) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AR-13324 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AMA-0076 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
(AR-12286 + travoprost) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ONO-9054 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ATS-907 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ATS-8535 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
latanoprost - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DE-117 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
travoprost Punctum Plug - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LIM-Kinase 1 And 2 Inhibitors - Drug Profile
Product Description
Mechanism of Action
R&D Progress
latanoprost - Drug Profile
Product Description
Mechanism of Action
R&D Progress
(bimatoprost + brimonidine) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PF-04475270 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
(latanoprost + dorzolamide) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VISION5 Product - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ocular Hypertension Therapeutics - Drug Profile Updates
Ocular Hypertension Therapeutics - Discontinued Products
Ocular Hypertension Therapeutics - Dormant Products
Ocular Hypertension - Product Development Milestones
Featured News & Press Releases
May 03, 2013: Amakem To Present Additional Data On AMA0076 At ARVO Annual Meeting
Apr 19, 2013: Alcon Receives FDA Approval For Simbrinza Suspension For Glaucoma Patients
Feb 19, 2013: Sucampo Announces Commercial Availability Of Rescula In US Pharmacies
Jan 18, 2013: Santen Pharma Receives Japanese Approval For Tapros Mini Ophthalmic Solution 0.0015% For Glaucoma And Ocular Hypertension Treatment
Dec 12, 2012: Sucampo Pharma Receives FDA Approval Of sNDA For Rescula
Nov 05, 2012: RegeneRx Receives Notice Of Allowance From US Patent Office For New Ophthalmic Indications
Sep 27, 2012: Amakem Initiates Phase IIa Proof Of Concept Study With AMA0076 In Patients With Glaucoma And Ocular Hypertension
Aug 20, 2012: Ocular Therapeutix Commences Pilot Phase II Travoprost Punctum Plug Study For Treatment Of Glaucoma
Jun 13, 2012: Zeltia Subsidiary Sylentis Commences Phase II Clinical Trial With SYL040012 For Treatment Of Ocular Hypertension Associated With Glaucoma
Apr 20, 2012: Senju Pharma To Launch AIPHAGAN Ophthalmic Solution In Japan
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products Under Development for Ocular Hypertension, H2 2013
Products under Development for Ocular Hypertension - Comparative Analysis, H2 2013
Number of Products under Development by Companies, H2 2013
Number of Products under Development by Companies, H2 2013 (Contd..1)
Comparative Analysis by Late Stage Development, H2 2013
Comparative Analysis by Mid Clinical Stage Development, H2 2013
Comparative Analysis by Early Clinical Stage Development, H2 2013
Comparative Analysis by Pre-Clinical Stage Development, H2 2013
Products under Development by Companies, H2 2013
Products under Development by Companies, H2 2013 (Contd..1)
Alcon, Inc., H2 2013
F. Hoffmann-La Roche Ltd., H2 2013
Bausch & Lomb Incorporated, H2 2013
Allergan, Inc., H2 2013
QLT Inc., H2 2013
Santen Pharmaceutical Co., Ltd., H2 2013
Sylentis, H2 2013
Novagali Pharma SA, H2 2013
Kowa Company, Ltd., H2 2013
Ono Pharmaceutical Co., Ltd., H2 2013
Pfizer Inc., H2 2013
Sun Pharmaceutical Industries Limited, H2 2013
Can-Fite BioPharma Ltd., H2 2013
Cancer Research Technology Limited, H2 2013
LABORATOIRES THEA, H2 2013
Asahi Kasei Pharma, H2 2013
Inotek Pharmaceuticals Corporation, H2 2013
Aerie Pharmaceuticals, Inc., H2 2013
Icon Bioscience, Inc., H2 2013
Assessment by Monotherapy Products, H2 2013
Assessment by Combination Products, H2 2013
Assessment by Stage and Route of Administration, H2 2013
Assessment by Stage and Molecule Type, H2 2013
Ocular Hypertension Therapeutics - Drug Profile Updates
Ocular Hypertension Therapeutics - Discontinued Products
Ocular Hypertension Therapeutics - Dormant Products

LIST OF FIGURES

Number of Products under Development for Ocular Hypertension, H2 2013
Products under Development for Ocular Hypertension - Comparative Analysis, H2 2013
Products under Development by Companies, H2 2013
Late Stage Products, H2 2013
Mid Clinical Stage Products, H2 2013
Early Clinical Stage Products, H2 2013
Pre-Clinical Stage Products, H2 2013
Assessment by Monotherapy Products, H2 2013
Assessment by Combination Products, H2 2013
Assessment by Route of Administration, H2 2013
Assessment by Stage and Route of Administration, H2 2013
Assessment by Molecule Type, H2 2013
Assessment by Stage and Molecule Type, H2 2013

COMPANIES MENTIONED

Alcon, Inc.
F. Hoffmann-La Roche Ltd.
Bausch & Lomb Incorporated
Allergan, Inc.
QLT Inc.
Santen Pharmaceutical Co., Ltd.
Sylentis
Novagali Pharma SA
Kowa Company, Ltd.
Ono Pharmaceutical Co., Ltd.
Pfizer Inc.
Sun Pharmaceutical Industries Limited
Can-Fite BioPharma Ltd.
Lexicon Pharmaceuticals, Inc.
Cancer Research Technology Limited
LABORATOIRES THEA
Asahi Kasei Pharma
Inotek Pharmaceuticals Corporation
Aerie Pharmaceuticals, Inc.
Icon Bioscience, Inc.
Ocular Inflammation - Pipeline Review, Q1 2011 US$ 500.00 Mar, 2011 · 45 pages
Ocular Inflammation - Pipeline Review, Q4 2010 US$ 500.00 Nov, 2010 · 50 pages
Portal Hypertension - Pipeline Review, Q4 2010 US$ 500.00 Dec, 2010 · 28 pages
Diabetic Hypertension - Pipeline Review, Q1 2011 US$ 500.00 Mar, 2011 · 18 pages

Ask Your Question

Ocular Hypertension - Pipeline Review, H2 2013
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: